Multicenter Trial Evaluating Quality of Tears Produced by Nasal Neurostimulation
- Conditions
- Dry Eye Syndromes
- Interventions
- Device: Oculeve Intranasal Lacrimal Neurostimulator
- Registration Number
- NCT02385292
- Lead Sponsor
- Oculeve, Inc.
- Brief Summary
The objectives of this study are:
* To compare the change in levels of tear proteins and inflammatory mediators pre and post administration between the intranasal and extranasal applications
* To compare the goblet cell count following application between the intranasal and extranasal applications
* To compare fluorescein tear clearance with the application of the device intranasally and extranasally applications
- Detailed Description
In this study, subjects will participate for three study days during up to a 44 day period, consisting of a screening examination to determine eligibility on one day and study applications on two different days. There are two applications, intranasal and extranasal. Subjects will receive both applications, in random sequence, one at each of the two application days (Visit 2 and Visit 3). The two applications consist of:
* Active intranasal device application
* Active extranasal device application
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 23
- Bilateral dry eyes
- Capable of providing written informed consent
- Chronic or recurring epistaxis (nosebleeds)
- Blood coagulation disorder
- Uncontrolled or poorly controlled diabetes
- Heart or pulmonary disease
- Females who are pregnant, planning a pregnancy or nursing
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Intranasal then Extranasal Application Oculeve Intranasal Lacrimal Neurostimulator Intranasal application of the Oculeve Intranasal Lacrimal Neurostimulator followed by extranasal application of the Oculeve Intranasal Lacrimal Neurostimulator. Extranasal then Intranasal Application Oculeve Intranasal Lacrimal Neurostimulator Extranasal application of the Oculeve Intranasal Lacrimal Neurostimulator followed by Intranasal application of the Oculeve Intranasal Lacrimal Neurostimulator.
- Primary Outcome Measures
Name Time Method Fluorescein Tear Clearance With Application Day 1
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Grutzmacher, Lewis & Sierra
🇺🇸Sacramento, California, United States
Baylor College of Medicine, Department of Ophthalmology
🇺🇸Houston, Texas, United States